Douglas Carsten > McDermott Will & Emery LLP > Irvine, United States > Lawyer Profile
McDermott Will & Emery LLP Offices
18565 JAMBOREE ROAD
SUITE 250
IRVINE, CA 92612
CALIFORNIA
United States
- Firm Profile
- Go to...
Douglas Carsten
Work Department
Intellectual Property
Position
Douglas (Doug) H. Carsten focuses his practice on complex patent litigation disputes. He counsels clients in various technology areas, including pharmaceuticals, biologics, medical devices, diagnostic products, retail products and computer software. He has substantial first-chair trial experience that includes litigating high-profile and billion-dollar patent cases. Doug is also co-chair of the Firm’s global Life Sciences practice.
Doug is an active speaker on topics relating to patent law, trial practice, Hatch-Waxman issues and oral presentation skills.
Please visit McDermott website for full biography: https://www.mwe.com/people/carsten-douglas-h/
Lawyer Rankings
United States > Intellectual property > Patents: litigation (full coverage)
The intellectual property team at McDermott Will & Emery LLP conducts complex IP litigation nationally and internationally, often securing victories in federal district and appellate courts, as well as appearing before the Patent Trial and Appeal Board. The group particularly excels in the healthcare, pharma and life sciences area, acting for the likes of Alnylam Pharmaceuticals, Amgen, Aurinia Pharmaceuticals, United Therapeutics, and Mylan Pharmaceuticals. Operating out of Silicon Valley, William (Bill) Gaede is the global head of the intellectual property practice group, with experience litigating life science technologies including antibodies, proteins, small molecules, and diagnostics. Douglas Carsten co-heads the team, leading the life sciences practice group out of Orange County.
United States > Healthcare > Life sciences
Douglas Carsten leads McDermott Will & Emery LLP’s life sciences industry group from Orange County. The ‘quality’ team exhibits ‘industry knowledge and innovative thinking‘ as it advises private equity and venture capital firms investing in life sciences on financings and deals, as well as digital health and technology companies seeking assistance regarding FDA and regulatory issues. Pollard primarily dispenses regulatory and corporate advice to medical device and biotech companies on matters concerning clinical research, post-market safety and compliance with FDA regulated products, and manufacturing. The ‘masterful‘ Carsten is a ‘tremendous litigator‘ who acts in lucrative patent and Hatch-Waxman cases. Working out of the Boston office, Sarah Chapin Columbia focuses on IP and patent litigation, while Michael Siekman assists with the development and defense of biotech patent portfolios and acquisitions. William Gaede supports the team from Silicon Valley with his experience in life science technology IP litigations concerning small molecules, proteins, and diagnostics. Counsel Anisa Mohanty, based in Washington DC, has extensive expertise in pre-market FDA strategy and post-market compliance, often advising medical product manufacturers and biotech companies. Vernessa Pollard departed the team to join DLA Piper LLP (US) in February 2024.
Lawyer Rankings
- Life sciences United States > Healthcare
- Patents: litigation (full coverage) United States > Intellectual property
Top Tier Firm Rankings
- Media, technology and telecoms > Technology transactions
- Healthcare > Health insurers
- Healthcare > Life sciences
- Media, technology and telecoms > Outsourcing
- Healthcare > Service providers
- Tax > US taxes: contentious
- Tax > US taxes: non-contentious
Firm Rankings
- Insurance > Advice to insurers
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy regulation: electric power
- Tax > Financial products
- Labor and employment > Immigration
- Tax > International tax
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Energy > Renewable/alternative power
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Labor and employment > ERISA litigation
- Dispute resolution > General commercial disputes
- Insurance > Insurance: non-contentious
- Labor and employment > Labor-management relations
- Antitrust > Merger control
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Real estate > Real estate finance
- International Trade > Trade remedies and trade policy
- Labor and employment > Workplace and employment counseling
- Finance > Capital markets: equity offerings
- Antitrust > Cartel
- Antitrust > Civil litigation/class actions: defense
- Energy > Energy transactions: electric power
- Energy > Energy transactions: oil and gas
- Labor and employment > Labor and employment disputes (including collective actions)
- Intellectual property > Patents: litigation (full coverage)
- Dispute resolution > Securities litigation: defense
- Finance > Structured finance: derivatives and structured products
- Dispute resolution > Corporate investigations and white-collar criminal defense
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Real estate > Real estate
- Finance > Restructuring (including bankruptcy): corporate
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Finance > Fintech
- Investment fund formation and management > Alternative/hedge funds
- Government > Government contracts